Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Excellent Outcomes Achieved with Medical Management of Chronic Phase CML Patients with Non-Hematologic TKI Intolerance

Kelly L. Schoenbeck, MD, Sirisha Tummala, MD, Rebecca L. Olin, MD, Neha G. Goyal, PhD, Anand Dhruva, MD, Lloyd E. Damon, MD, Aaron C. Logan, MDPhDMPhil, Catherine C. Smith, MD, Neil P. Shah, MDPhD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-143303

Published: 2020

Journal Articles

Efficacy of Venetoclax Combination Therapy with Hypomethylating Agents in Patients with Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Varun Mittal, MD, Mimi Lo, PharmD, Lloyd E. Damon, MD, Karin L. Gaensler, MD, Thomas G. Martin, III, MD, Rebecca L. Olin, MD, Catherine C. Smith, MD, Aaron C. Logan, MD PhD

Blood (2019) 134 (Supplement_1): 5089.

https://doi.org/10.1182/blood-2019-129514

Published: 2019

Journal Articles

Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution

Kelly L. Schoenbeck, MD, Miguel Carlos Cerejo, DO, Patricia A. Cornett, MD, Lloyd E. Damon, MD, Karin L. Gaensler, MD, Andrew D. Leavitt, MD, Aaron C. Logan, MD PhD, Gabriel N. Mannis, MD, Rebecca L. Olin, MD, Giselle Salmasi, MD, Peter H. Sayre, MD PhD, Neil P. Shah, MD PhD, Anand Dhruva, MD, Chloe E. Atreya, MD PhD, Catherine C. Smith, MD

Blood (2019) 134 (Supplement_1): 5859.

https://doi.org/10.1182/blood-2019-129638

Published: 2019

Journal Articles

Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms

Kelly L. Schoenbeck, MD, Giselle Salmasi, MD, Miguel Carlos Cerejo, DO, Patricia A. Cornett, MD, Lloyd E. Damon, MD, Aaron C. Logan, MD PhD, Rebecca L. Olin, MD, Andrew D. Leavitt, MD, Catherine C. Smith, MD

Blood (2019) 134 (Supplement_1): 1165.

https://doi.org/10.1182/blood-2019-129705

Published: 2019

Journal Articles

Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504

Marc Schwartz, MD, Lloyd E. Damon, MD, Deepa Jeyakumar, MD, Caitlin L. Costello, MD, Dimitrios Tzachanis, MD PhD, Gary J. Schiller, MD, Jesika Reiner, MPH, Matthew J. Wieduwilt, MD PhD

Blood (2019) 134 (Supplement_1): 3880.

https://doi.org/10.1182/blood-2019-131061

Published: 2019

Journal Articles

A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401

Matthew J. Wieduwilt, MD PhD, Brian A. Jonas, MD, Gary J. Schiller, MD, Lin Liu, PhD, Carolyn Mulroney, MD, Gabriel N. Mannis, MD, Dimitrios Tzachanis, MD PhD, Januario E. Castro, MD, Edward D Ball, MD, Peter T. Curtin, MD, Charalambos Andreadis, MD, Aaron C. Logan, MD PhD, Jesika Reiner, MPH, Lloyd E. Damon, MD

Blood (2018) 132 (Supplement 1): 4018.

https://doi.org/10.1182/blood-2018-99-117469

Published: 2018

Journal Articles

Functional Status Is Associated with Outcomes after Allogeneic Stem Cell Transplantation for Older Patients with Hematologic Malignancies

Li-Wen Huang, MD, Chiung-Yu Huang, PhD, Charalambos Andreadis, MD, Aaron C. Logan, MD PhD, Gabriel N. Mannis, MD, Catherine C. Smith, MD, Karin M. Gaensler, MD, Thomas G. Martin, III, MD, Lloyd E. Damon, MD, Michael A. Steinman, MD, Rebecca L. Olin, MD

Blood (2018) 132 (Supplement 1): 3599.

https://doi.org/10.1182/blood-2018-99-112025

Published: 2018

Journal Articles

Impact of Demographic and Socioeconomic Factors on Outcomes Following Allogeneic Hematopoietic Cell Transplantation

Nicole Foley, Jimmy Hwang, PhD, Nina Balsamo, MSW, Lia Akhilanda, MSW, Lloyd E. Damon, MD, Rebecca L. Olin, MD MS, Gabriel N. Mannis, MD, Aaron C. Logan, MDPhDMPhil

Blood (2017) 130 (Supplement 1): 4570.

https://doi.org/10.1182/blood.V130.Suppl_1.4570.4570

Published: 2017

Journal Articles

The Role of Comprehensive Mutational Profiling in Predicting Patients Who May Benefit from Autologous Hematopoietic Cell Transplant for Acute Myeloid Leukemia

Gabriel N. Mannis, MD, Nicole Therrien, Jessica Van Ziffle, Nicole Foley, Iwei Yeh, Shan Zhong, PhD, Jie He, PhD, Michelle Nahas, PhD, Charalambos Andreadis, MD MSCE, Lloyd E. Damon, MD, Rebecca L. Olin, MD MS, Sonam Prakash, MD, Tariq I Mughal, MD FRCP, Aaron C. Logan, MDPhDMPhil, Thomas G. Martin, III, MD

Blood (2017) 130 (Supplement 1): 1423.

https://doi.org/10.1182/blood.V130.Suppl_1.1423.1423

Published: 2017

Journal Articles

Cell of Origin and Double Protein Expression As Predictors of Outcome after Autologous Stem Cell Transplant for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Undergo Intensive Consolidation Therapy (ICT) and Autologous Stem Cell Transplant (AutoSCT)

Bradley Hunter, MD MPH, Ben Rosen, MD, Miguel Castillo, Lawrence D. Kaplan, MD, Weiyun Z. Ai, MD PhD, Lloyd E. Damon, MD, Thomas G. Martin, III, MD, Charalambos Andreadis, MD MSCE

Blood (2016) 128 (22): 4638.

https://doi.org/10.1182/blood.V128.22.4638.4638

Published: 2016

Journal Articles

Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk Following Autologous Hematopoietic Cell Transplantation

Gabriel N. Mannis, MD, Thomas G. Martin, III, MD, Lloyd E. Damon, MD, Charalambos Andreadis, MD MSCE, Rebecca L. Olin, MD MSCE, Katie Kong, Malek Faham, MD PhD, Weiyun Z. Ai, MD PhD, Karin ML Gaensler, MD, Peter H. Sayre, MD PhD, Jeffrey L. Wolf, MD PhD, Aaron C. Logan, MD PhD

Blood (2015) 126 (23): 1420.

https://doi.org/10.1182/blood.V126.23.1420.1420

Published: 2015

Journal Articles

Marqibo®, Vincristine Sulfate Liposome Injection, for the Treatment of Advanced, Relapsed or Refractory Philadelphia Chromosome-Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) in an Adolescent Young Adult (AYA) Population

Gary J Schiller, MD, Lloyd E. Damon, MD, Wendy Stock, MD, Steven E Coutre, MD, Pamela Hsu, Lucy Prasad, Dan Douer, MD

Blood (2015) 126 (23): 1291.

https://doi.org/10.1182/blood.V126.23.1291.1291

Published: 2015

Journal Articles

Panobinostat-Augmented Cytarabine and Daunorubicin (7+3) Induction for Older Patients with AML or High-Risk MDS Is Well Tolerated and Results in Favorable Clinical Outcomes: The Panda Trial

Matthew J. Wieduwilt, MD PhD, Scott Thomas, PhD, Rebecca L. Olin, MD MSCE, Aaron C. Logan, MDPhD, Lloyd E. Damon, MD, Thomas G. Martin, III, MD, McNancy Kang, Peter H. Sayre, MD PhD, Wanda Boyer, NP,MSN, Karin ML Gaensler, MD, Kirsten Anderson, Pamela Munster, MD, Charalambos Andreadis, MD MSCE

Blood (2015) 126 (23): 1337.

https://doi.org/10.1182/blood.V126.23.1337.1337

Published: 2015

Journal Articles

Multigene MRD Assessment Improves AML Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation

Matthew P. Mulé, BS, Gabriel N. Mannis, MD, Jerald P. Radich, MD, Brent L. Wood, MDPhD, Nestor R. Ramos, MD, Catherine E. Lai, MD, Michael Flanders, BA, Charalambos Andreadis, MD MSCE, Lloyd E. Damon, MD, Aaron C. Logan, MDPhD, Thomas G. Martin, MD, Christopher S. Hourigan, MDPhD

Blood (2015) 126 (23): 4350.

https://doi.org/10.1182/blood.V126.23.4350.4350

Published: 2015

Journal Articles

Comparison Of Deep Sequencing and Allele-Specific Oligonucleotide PCR Methods For MRD Quantitation In Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma: CALGB 10403 and CALGB 59909 (Alliance)

Greg Malnassy, MS, Susan Geyer, PhD, Noreen Fulton, B.S., Greg Koval, B.S., Donna Niedzwiecki, PhD, Victoria Carlton, PhD, Li Weng, PhD, Lawrence D. Kaplan, MD, Guido Marcucci, MD, Lloyd E Damon, MD, Richard A. Larson, MD, Richard M. Stone, MD, Bruce D. Cheson, M.D., Malek Faham, MD, PhD, Wendy Stock, M.D.

Blood (2013) 122 (21): 2547.

https://doi.org/10.1182/blood.V122.21.2547.2547

Published: 2013

Journal Articles

Autologous Transplantation Is Safe and Effective For Patients With Multiple Myeloma Related Renal Insufficiency

Claire C Greene, BA, Jimmy Hwang, PhD, Jeffrey Lee Wolf, MD, Lloyd E Damon, MD, Anuj Mahindra, MD, Thomas G Martin, III, MD

Blood (2013) 122 (21): 3388.

https://doi.org/10.1182/blood.V122.21.3388.3388

Published: 2013

Journal Articles

Delayed Hematopoietic Recovery After Autologous Stem Cell Transplantation In Patients Receiving Arsenic Trioxide-Based Therapy For Acute Promyelocytic Leukemia

Gabriel N. Mannis, MD, Lloyd E Damon, MD, Weiyun Z. Ai, MD, PhD, Charalambos Andreadis, MD, MS, Karin ML Gaensler, MD, Neel K. Gupta, M.D., Lawrence D. Kaplan, M.D., Andrew D. Leavitt, MD, Aaron C. Logan, MD, PhD, Rebecca L. Olin, MD, MS, Peter H. Sayre, MD, PhD, Catherine C Smith, MD, Jeffrey M Venstrom, MD, Thomas G Martin, III, MD

Blood (2013) 122 (21): 2172.

https://doi.org/10.1182/blood.V122.21.2172.2172

Published: 2013

Journal Articles

Neurological Toxicity Profile of Weekly Vincristine Sulfate Liposomes Injection (Marqibo ® ) 2.25 mg/m 2 Compared to Historical Standard Vincristine Sulfate 1.4 mg/m 2 , 2 mg, and 4 mg Administered Less Frequently

Lloyd E. Damon, MD, Stuart L. Goldberg, MD, Leonard T. Heffner, MD, John Lister, MD, Gary J. Schiller, MD, Steven R. Deitcher, MD

Blood (2011) 118 (21): 4247.

https://doi.org/10.1182/blood.V118.21.4247.4247

Published: 2011

Journal Articles

Vincristine Sulfate Liposomes Injection (Marqibo ® ) Facilitates Durable Remissions and Potentially Curative Hematopoietic Stem Cell Transplantation in Adults with Advanced, Relapsed and/or Refractory Acute Lymphoblastic Leukemia

Gary J. Schiller, MD, John Lister, MD, Leonard T. Heffner, MD, Stuart L. Goldberg, MD, Lloyd E. Damon, MD, Jeffrey A. Silverman, Ph.D., Steven R. Deitcher, MD

Blood (2011) 118 (21): 4235.

https://doi.org/10.1182/blood.V118.21.4235.4235

Published: 2011

Journal Articles

Multicenter Phase I Trial of Intraventricular Immuno-Chemotherapy in Recurrent CNS Lymphoma

James L. Rubenstein, M.D., Ph.D., Lingjing Chen, Ph.D., Ranjana Advani, MD, Jan Drappatz, M.D., Elizabeth Gerstner, M.D., Tracy Batchelor, MD, Hendrikus Krouwer, M.D., Cigall Kadoch, BA, Pamela Munster, MD, Soonmee Cha, M.D., Marc A Shuman, MD, Lloyd E. Damon, MD

Blood (2011) 118 (21): 959.

https://doi.org/10.1182/blood.V118.21.959.959

Published: 2011

NARROW

Excellent Outcomes Achieved with Medical Management of Chronic Phase CML Patients with Non-Hematologic TKI Intolerance

Efficacy of Venetoclax Combination Therapy with Hypomethylating Agents in Patients with Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution

Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms

Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504

Functional Status Is Associated with Outcomes after Allogeneic Stem Cell Transplantation for Older Patients with Hematologic Malignancies

Impact of Demographic and Socioeconomic Factors on Outcomes Following Allogeneic Hematopoietic Cell Transplantation

The Role of Comprehensive Mutational Profiling in Predicting Patients Who May Benefit from Autologous Hematopoietic Cell Transplant for Acute Myeloid Leukemia

Cell of Origin and Double Protein Expression As Predictors of Outcome after Autologous Stem Cell Transplant for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Undergo Intensive Consolidation Therapy (ICT) and Autologous Stem Cell Transplant (AutoSCT)

Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk Following Autologous Hematopoietic Cell Transplantation

Marqibo®, Vincristine Sulfate Liposome Injection, for the Treatment of Advanced, Relapsed or Refractory Philadelphia Chromosome-Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) in an Adolescent Young Adult (AYA) Population

Panobinostat-Augmented Cytarabine and Daunorubicin (7+3) Induction for Older Patients with AML or High-Risk MDS Is Well Tolerated and Results in Favorable Clinical Outcomes: The Panda Trial

Multigene MRD Assessment Improves AML Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation

Comparison Of Deep Sequencing and Allele-Specific Oligonucleotide PCR Methods For MRD Quantitation In Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma: CALGB 10403 and CALGB 59909 (Alliance)

Autologous Transplantation Is Safe and Effective For Patients With Multiple Myeloma Related Renal Insufficiency

Delayed Hematopoietic Recovery After Autologous Stem Cell Transplantation In Patients Receiving Arsenic Trioxide-Based Therapy For Acute Promyelocytic Leukemia

Neurological Toxicity Profile of Weekly Vincristine Sulfate Liposomes Injection (Marqibo ® ) 2.25 mg/m 2 Compared to Historical Standard Vincristine Sulfate 1.4 mg/m 2 , 2 mg, and 4 mg Administered Less Frequently

Vincristine Sulfate Liposomes Injection (Marqibo ® ) Facilitates Durable Remissions and Potentially Curative Hematopoietic Stem Cell Transplantation in Adults with Advanced, Relapsed and/or Refractory Acute Lymphoblastic Leukemia

Multicenter Phase I Trial of Intraventricular Immuno-Chemotherapy in Recurrent CNS Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only